Heron Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HRTX research report →
Range $5 – $9
Price Chart
About the company
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents.
- CEO
- Craig Alexander Collard
- IPO
- 1987
- Employees
- 128
- HQ
- Cary, NC, US
Get TickerSpark's AI analysis on HRTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $48.04M
- P/E
- -2.33
- Fwd P/E
- 7.21
- PEG
- 0.03
- P/S
- 0.34
- P/B
- 10.26
- EV/EBITDA
- -11.13
- Div Yield
- 0.00%
- Gross Margin
- 73.81%
- Op Margin
- -5.69%
- Net Margin
- -14.55%
- ROE
- -244.35%
- ROIC
- -5.99%
Latest fiscal year · YoY change
- Revenue
- $154.90M+7.4%
- Gross Profit
- $113.56M+7.5%
- Op Income
- $-2,538,000
- Net Income
- $-20,195,000-48.7%
- EPS
- $-0.12-34.7%
- OCF Growth
- -22.5%
- FCF Growth
- -15.2%
- 52W High
- $1.58
- 52W Low
- $0.25
- 50D MA
- $0.32
- 200D MA
- $0.62
- Beta
- 1.65
- RSI (14)
- 37
- Avg Volume
- 4.58M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Heron posted $37.7 million in Q2 net revenue with solid acute-care growth, but pulled full-year guidance after the CINVANTI court ruling, tightened spending, and reset its debt structure.· August 10, 2026
- Total net revenue was $37.7 million, up from $34.7 million in Q1, with gross margin at 69.3%.
- Acute care grew 44% year over year; ZYNRELEF sales were $11.1 million and APONVIE sales were $4.2 million.
- CINVANTI sales were $21.8 million, down about 10% year over year, and management is preparing for potential generic competition.
- Heron withdrew full-year 2026 guidance because CINVANTI generic timing is uncertain, spending plans changed, and strategic alternatives are being considered.
- The company amended its Hercules credit facility, reduced principal, and said it will report cash, spending, and covenant compliance quarterly instead of giving annual guidance.
Net revenues were $37.7 million in Q2 2026, versus $34.7 million in Q1 2026 and $37.2 million in the prior-year quarter. Gross margin was 69.3%. R&D expense was $2.7 million, SG&A was $25.4 million, operating loss was $2.0 million, and net loss was $5.5 million versus a $2.4 million net loss in the comparable prior-year quarter. Adjusted EBITDA was $3.2 million, up from $2.2 million a year ago. Management withdrew full-year 2026 guidance of $173 million to $183 million in net product sales and $10 million to $20 million in adjusted EBITDA, citing uncertainty around CINVANTI generic timing, the pause in sales force expansion, and strategic alternatives.
Craig Collard framed the quarter as below expectations but said the company is responding decisively. He highlighted three priorities: resetting the balance sheet, tightening spending after the June court decision on CINVANTI patents, and defending the oncology franchise while preparing for possible generic competition. His tone was candid and defensive, emphasizing that spending decisions will follow what the business demonstrates rather than prior plans, and that strategic alternatives are being considered without a set timetable.
Ira Duarte focused on discipline and balance sheet actions. He said the company ended the quarter with $42.7 million in cash, cash equivalents, and short-term investments, and that the Hercules amendment waives June 30 covenants and resets the schedule through December 2027. The amendment includes a $13.5 million principal reduction plus fees at execution and a potentially further $4 million reduction by September 15, bringing pro forma cash to about $28.5 million, or about $24.3 million after the September payment. He also said the company is withdrawing annual guidance and will instead report cash, spending, and covenant compliance each quarter.
Analysts pressed on covenant protection if a CINVANTI generic launches, and Craig said the company took a conservative view because launch timing is unclear, manufacturing could take time, reimbursement could vary, and the lender was comfortable with the downside case. On whether CINVANTI erosion would resemble SUSTOL, management did not give a direct curve comparison but said the company is preparing for potential competition and that settlement agreements would not be affected by a launch. Questions on ZYNRELEF focused on weaker-than-expected execution and possible macro softness; Mark Hensley said the issue was more about timing and execution than the product itself, and that Q2 was slower than expected but the back half should improve.
The call showed clear growth in the acute care franchise, with ZYNRELEF up 35% year over year and APONVIE up 74% year over year. Management also pointed to stronger positioning in ZYNRELEF accounts, APONVIE share gains, and a stable recent run-rate for CINVANTI despite branded competition. The lender amendment and spending reset may give the company more flexibility to navigate uncertainty.
The biggest risk is CINVANTI: management said the June patent decision changed the outlook and that potential generic timing is unknown, which is why full-year guidance was withdrawn. ZYNRELEF also came in below expectations, and management admitted Q2 execution was slower than planned. The company is tightening spending and considering strategic alternatives, which underscores how much uncertainty remains around the business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.2%
- Shares Outstanding
- 190.27M
- Float Shares
- 146.80M
of shares held by institutions
170 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HRTX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ashley HinsonHouse · IA01 | Sell | Mar 31, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rubric Capital Management LP | 30.05M | 0 |
| Clearline Capital LP | 11.38M | ▼ 851.28K |
| Blackrock, Inc. | 9.83M | ▼ 724.42K |
| Vanguard Group Inc | 9.82M | ▲ 1.36M |
| Velan Capital Investment Management LP | 8.75M | 0 |
| Vanguard Capital Management LLC | 7.82M | ▲ 37.42K |
| Tejara Capital Ltd | 6.49M | ▼ 17.92K |
| Tang Capital Management LLC | 6.25M | 0 |
| Geode Capital Management, LLC | 4.11M | ▼ 164.96K |
| Millennium Management LLC | 4.07M | ▼ 3.56M |
| State Street Corp | 3.20M | ▼ 25.16K |
| Pale Fire Capital Se | 2.51M | ▼ 204.85K |
Held by 111 ETFs
Biggest fund positions in HRTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Hensley Mark Earl | other | 31,250 |
| Nov 6, 26 | Hensley Mark Earl | other | 31,250 |
| Nov 6, 26 | Hensley Mark Earl | other | 8,889 |
| Oct 31, 26 | Collard Craig A | other | 34,788 |
| Oct 31, 26 | Collard Craig A | other | 8,471 |
| Oct 30, 26 | Collard Craig A | other | 50,021 |
| Oct 30, 26 | Collard Craig A | other | 12,181 |
| Oct 30, 26 | Collard Craig A | other | 50,021 |
| Oct 31, 26 | Collard Craig A | other | 34,788 |
| Oct 31, 26 | Duarte Ira | other | 11,695 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HRTX coverage
Recent articles, reports, and earnings notes.
No research on HRTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HRTX report →CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
zacks.com · Nov 10
Heron Therapeutics, Inc. (HRTX) M&A Call Transcript
seekingalpha.com · Nov 10
CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal
benzinga.com · Nov 9
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 9
Heron Therapeutics Announces Third Quarter 2026 Financial Results
globenewswire.com · Nov 9
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
globenewswire.com · Nov 9
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
globenewswire.com · Oct 26
Head-To-Head Review: Heron Therapeutics (NASDAQ:HRTX) vs. Sol-Gel Technologies (NASDAQ:SLGL)
defenseworld.net · Sep 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.